Get the latest tech news
The Alzheimer’s drug pipeline is healthier than you might think
It reflects a more nuanced understanding of the disease
OF ALL THE medical challenges that scientists have faced, Alzheimer’s disease, the most common form of dementia, has been one of the trickiest. Between 1995 and 2021 private money spent on Alzheimer’s research totalled $42.5bn, but more than 140 trials failed to deliver a single drug capable of slowing the disease. There are two working drugs, offering modest benefits, on the market.
Or read this on r/technology
